Spruce Biosciences Q3 2026 Results: Net Loss of $24M, Loss Widens
Spruce Biosciences reported a significant increase in cash and cash equivalents to $87.7 million as of September 30, 2026, compared to $48.9 million at year-end 2025. However, the company faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $341.7 million and a need for additional financing to develop its lead product candidate, tralesinidase alfa (TA-ERT).
- Key figure
- Net loss $24M